Literature DB >> 25059395

Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Meinie Seelen1, Perry T C van Doormaal, Anne E Visser, Mark H B Huisman, Margot H J Roozekrans, Sonja W de Jong, Anneke J van der Kooi, Marianne de Visser, Nicol C Voermans, Jan H Veldink, Leonard H van den Berg.   

Abstract

Sporadic amyotrophic lateral sclerosis (ALS) is believed to be a complex disease in which multiple exogenous and genetic factors interact to cause motor neuron degeneration. Elucidating the association between medical conditions prior to the first symptoms of ALS could lend support to the theory that specific subpopulations are at risk of developing ALS and provide new insight into shared pathogenic mechanisms. We performed a population-based case-control study in the Netherlands, including 722 sporadic ALS patients and 2,268 age and gender matched controls. Data on medical conditions and use of medication were obtained through a structured questionnaire. Multivariate analyses showed that hypercholesterolemia (OR 0.76, 95% CI 0.63-0.92, P = 0.006), the use of statins (OR 0.45, 95% CI 0.35-0.59, P = 1.86 × 10(-9)) or immunosuppressive drugs (OR 0.26, 95% CI 0.08-0.86, P = 0.03) were associated with a decreased risk of ALS. Head trauma was associated with an increased ALS susceptibility (OR 1.95, 95% CI 1.11-3.43, P = 0.02). No association was found with autoimmune diseases, cancer, psychiatric disorders or cardiovascular diseases, or survival. The lower frequency of hypercholesterolemia and less use of statins in ALS patients indicate a favorable lipid profile prior to symptom onset in at least a subpopulation of ALS. Prior head trauma is a risk factor for ALS and the significantly lower use of immunosuppressive drugs in ALS patients could suggest a protective effect. The identification of specific subpopulations at risk for ALS may provide clues towards possible pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25059395     DOI: 10.1007/s00415-014-7445-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  38 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study.

Authors:  Martin R Turner; Clare Wotton; Kevin Talbot; Michael J Goldacre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-11-09       Impact factor: 10.154

3.  Recall bias in epidemiologic studies.

Authors:  S S Coughlin
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

4.  Amyotrophic lateral sclerosis after embolization of cerebral arterioveneous malformations.

Authors:  Anton Valavanis; Urs Schwarz; Christian R Baumann; Michael Weller; Michael Linnebank
Journal:  J Neurol       Date:  2014-02-08       Impact factor: 4.849

5.  An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.

Authors:  Eric Colman; Ana Szarfman; Jo Wyeth; Andrew Mosholder; Devanand Jillapalli; Jonathan Levine; Mark Avigan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-11       Impact factor: 2.890

6.  Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.

Authors:  Luc Dupuis; Hugues Oudart; Frédérique René; Jose-Luis Gonzalez de Aguilar; Jean-Philippe Loeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

7.  Are statin medications safe in patients with ALS?

Authors:  Lorne Zinman; Reza Sadeghi; Marek Gawel; Dan Patton; Alex Kiss
Journal:  Amyotroph Lateral Scler       Date:  2008-08

8.  Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.

Authors:  L Dupuis; P Corcia; A Fergani; J-L Gonzalez De Aguilar; D Bonnefont-Rousselot; R Bittar; D Seilhean; J-J Hauw; L Lacomblez; J-P Loeffler; V Meininger
Journal:  Neurology       Date:  2008-01-16       Impact factor: 9.910

9.  Statin use and the risk of Parkinson disease.

Authors:  Angelika D Wahner; Jeff M Bronstein; Yvette M Bordelon; Beate Ritz
Journal:  Neurology       Date:  2008-01-09       Impact factor: 9.910

10.  Hypermetabolism in ALS patients: an early and persistent phenomenon.

Authors:  C Bouteloup; J-C Desport; P Clavelou; N Guy; H Derumeaux-Burel; A Ferrier; P Couratier
Journal:  J Neurol       Date:  2009-03-22       Impact factor: 4.849

View more
  34 in total

1.  Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: A population based study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ryan M Seals; Ole Gredal; Murray A Mittleman; Johnni Hansen; Marc G Weisskopf
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-07-20       Impact factor: 4.092

2.  Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.

Authors:  Sebastian A Lewandowski; Ingrid Nilsson; Linda Fredriksson; Peter Lönnerberg; Lars Muhl; Manuel Zeitelhofer; Milena Z Adzemovic; Susanne Nichterwitz; Daniel A Lawrence; Eva Hedlund; Ulf Eriksson
Journal:  Acta Neuropathol       Date:  2015-12-19       Impact factor: 17.088

3.  Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS).

Authors:  Thomas Kuczmarski; Elijah W Stommel; Kristen Riley; Rup Tandan; Vinay Chaudhry; Lora Clawson; Tracie A Caller; Patricia L Henegan; Dominic N Facciponte; Walter G Bradley; Angeline S Andrew
Journal:  J Neurol       Date:  2017-07-15       Impact factor: 4.849

4.  Meta-analytic evaluation of the association between head injury and risk of amyotrophic lateral sclerosis.

Authors:  Yukari Watanabe; Takamitsu Watanabe
Journal:  Eur J Epidemiol       Date:  2017-10-27       Impact factor: 8.082

Review 5.  Defining pre-symptomatic amyotrophic lateral sclerosis.

Authors:  Michael Benatar; Martin R Turner; Joanne Wuu
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-03-20       Impact factor: 4.092

6.  Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ran S Rotem; Ryan M Seals; Ole Gredal; Johnni Hansen; Marc G Weisskopf
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

Review 7.  Potential Environmental Factors in Amyotrophic Lateral Sclerosis.

Authors:  Björn Oskarsson; D Kevin Horton; Hiroshi Mitsumoto
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

8.  Associations between co-medications and survival in ALS-a cohort study from Austria.

Authors:  Hakan Cetin; Uros Klickovic; Jakob Rath; Gudrun Zulehner; Judith Füzi; Berthold Reichardt; Michael Hagmann; Julia Wanschitz; Wolfgang N Löscher; Eduard Auff; Fritz Zimprich
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

Review 9.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

10.  Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.

Authors:  Xiaowei W Su; Wint Nandar; Elizabeth B Neely; Zachary Simmons; James R Connor
Journal:  Muscle Nerve       Date:  2016-05-19       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.